Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 1, Pages 40
Publisher
MDPI AG
Online
2021-01-07
DOI
10.3390/ph14010040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA
- (2020) Kodandaram Pillarisetti et al. BLOOD
- First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma
- (2020) Ravi Vij et al. CLINICAL CANCER RESEARCH
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
- (2020) Lijie Xing et al. LEUKEMIA
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Immunotherapy of multiple myeloma
- (2020) Simone A. Minnie et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
- (2020) Hans C. Lee et al. LEUKEMIA
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
- (2020) Chiara Caraccio et al. Frontiers in Immunology
- Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
- (2020) Margaux Lejeune et al. Frontiers in Immunology
- Targeted Therapy With Immunoconjugates for Multiple Myeloma
- (2020) Wassilis S. C. Bruins et al. Frontiers in Immunology
- Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
- (2020) Kodandaram Pillarisetti et al. Blood Advances
- Bispecifics, trispecifics, and other novel immune treatments in myeloma
- (2020) Guido Lancman et al. Hematology-American Society of Hematology Education Program
- Future of CAR T cells in multiple myeloma
- (2020) Kitsada Wudhikarn et al. Hematology-American Society of Hematology Education Program
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
- (2019) Roman H Khadka et al. Immunotherapy
- The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT
- (2019) Hermann Einsele et al. BONE MARROW TRANSPLANTATION
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
- (2019) Nirav N. Shah et al. BLOOD
- Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)
- (2019) Paul G. Richardson et al. BLOOD
- Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Katja Weisel et al. BLOOD
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
- (2019) Francesca Bonello et al. Cancers
- How I treat the young patient with multiple myeloma
- (2018) Sara Gandolfi et al. BLOOD
- Bispecific antibody based therapeutics: Strengths and challenges
- (2018) Archana Thakur et al. BLOOD REVIEWS
- Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
- (2018) Hui Zhao et al. CANCER RESEARCH
- Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies
- (2018) Alex F. Herrera et al. Clinical Lymphoma Myeloma & Leukemia
- The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker
- (2018) Eric Sanchez et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
- (2018) Krista Kinneer et al. LEUKEMIA
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
- (2018) Cristina L. Abrahams et al. Oncotarget
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- (2017) Kurt Schönfeld et al. Journal of Hematology & Oncology
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
- (2017) Francesca Gay et al. HAEMATOLOGICA
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
- (2016) Camille Guillerey et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
- (2016) P. Neri et al. CLINICAL CANCER RESEARCH
- Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
- (2016) Daniel W. Sherbenou et al. JOURNAL OF CLINICAL INVESTIGATION
- Genomic complexity of multiple myeloma and its clinical implications
- (2016) Salomon Manier et al. Nature Reviews Clinical Oncology
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
- (2016) N. V. Frey et al. Hematology-American Society of Hematology Education Program
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
- (2015) T Dosani et al. Blood Cancer Journal
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Evaluation of TNF superfamily molecules in multiple myeloma patients: Correlation with biological and clinical features
- (2013) Dorota Lemancewicz et al. LEUKEMIA RESEARCH
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started